GGD Ams­ter­dam par­tic­i­pates in the large inter­na­tion­al PrEP-study DISCOVER. This study is to estab­lish the safe­ty and effec­tive­ness of the new pill F/TAF in com­par­i­son to the exist­ing PrEP pill Tru­va­da. You can apply until the 26th of March.

About the DIS­COV­ER-study

The DIS­COV­ER-study is designed by Gilead, man­u­fac­tur­er of both Tru­va­da and F/TAF. Unlike the H-TEAM’s AMPrEP-study, DISCOVER (also con­duct­ed at GGD Ams­ter­dam) stud­ies the effec­tive­ness and safe­ty of the new pill as PrEP.

Half of the par­tic­i­pants will get Tru­va­da, the oth­er half will get the new pill F/TAF. Par­tic­i­pants nor research staff will know who gets which pill. F/TAF is already avail­able for HIV treat­ment but its effec­tive­ness as PrEP had not yet been sci­en­tif­i­cal­ly researched.

Who can sign up for the study?

PrEP is meant as an extra pre­ven­tion tool for HIV neg­a­tive peo­ple who have a sub­stan­tial risk for HIV infec­tion. Gay men and oth­er men who have sex with men and trans­gen­der women can sign up for DISCOVER on the GGD’s web­site.

Alter­na­tive: DIY-PrEP

More peo­ple choose to buy their gener­ic PrEP abroad or online. Next week you’ll find infor­ma­tion on explain­ing how to do this safe­ly and reli­ably.

Last updated 29/08/2019